Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s second-quarter that reveal it is heading for the sixth straight quarter of record revenue.
The company said it expects 2Q revenue to exceed $13.5 million while its adjusted underlying (EBITDA) loss will decrease to below $2 million as the company heads to profitability.
Saviuk told Proactive the number continues to be driven by Asthma medications ENERZAIR and ATECTURA which saw quarterly revenues grow 270% over this time last year. In fact, the total number of prescribing physicians also grew and is now expected to exceeds 2,000.
Contact Details
Proactive Investors
+1 347-449-0879
